 This study found that direct acting antivirals, DAAs, are an effective treatment option for chronic hepatitis C, CHC, in patients with chronic kidney disease, CKD. The study also showed that DAAs can be safely used in these patients without any significant side effects. This article was authored by Paulina Zarnaca, King Nazarnaca, Old Atronina, and others.